Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial

SUMMARY: Abaloparatide increased ultradistal radius bone mineral density (BMD) in the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial. Over the subsequent 24 months in ACTIVExtend, ultradistal radius BMD gains were maintained with alendronate. Conversely, 1/3 radius BMD remained...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Osteoporos Int
Main Authors: Watts, N.B., Dore, R.K., Baim, S., Mitlak, B., Hattersley, G., Wang, Y., Rozental, T.D., LeBoff, M.S.
Format: Artigo
Jezik:Inglês
Izdano: Springer London 2020
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755646/
https://ncbi.nlm.nih.gov/pubmed/32935170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-020-05555-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki